Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on IGM Biosciences (IGMS – Research Report) and Argenx Se (ARGX – Research Report).
IGM Biosciences (IGMS)
H.C. Wainwright analyst Robert Burns reiterated a Hold rating on IGM Biosciences today and set a price target of $12.00. The company’s shares closed last Wednesday at $8.13.
According to TipRanks.com, Burns is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on IGM Biosciences is a Moderate Buy with an average price target of $23.00.
See today’s best-performing stocks on TipRanks >>
Argenx Se (ARGX)
H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Argenx Se today and set a price target of $451.00. The company’s shares closed last Wednesday at $366.20.
According to TipRanks.com, Tsao is a 4-star analyst with an average return of
Argenx Se has an analyst consensus of Moderate Buy, with a price target consensus of $465.87, implying a 27.5% upside from current levels. In a report issued on April 12, Bank of America Securities also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on IGMS:
- IGM Biosciences Announces Refocusing of Sanofi Collaboration
- IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology Forum
- IGM Biosciences price target raised to $12 from $7 at H.C. Wainwright
- Igm Biosciences Is Worried About This – Should You Be Worried Too?
- IGM Biosciences sees FY24 operating expenses $210M-$220M
